Clinical Trials
21 trialsNCT05319730 2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06445972 2026-05-12
MK-3475-06D
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04540211 2026-04-09
SKYSCRAPER-08
Hoffmann-La Roche
Phase 3 Completed
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT05342636 2025-12-17
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03281369 2025-12-15
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02013154 2025-08-03
P102
Leap Therapeutics, Inc.
Phase 1 Completed
NCT05191667 2025-02-13
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Suspended
NCT03165994 2024-05-02
APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers
Apexigen America, Inc.
Phase 2 Completed
NCT03748134 2023-10-24
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03933449 2023-03-29
KEYNOTE-181
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02564263 2023-03-13
KEYNOTE-181
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02569242 2022-07-06
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
Ono Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT02970539 2022-02-16
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers
Athenex, Inc.
Phase 1 Unknown
NCT04426955 2021-09-16
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT01822613 2020-12-19
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
Novartis
Phase 1 Completed
NCT01774851 2017-06-22
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Merrimack Pharmaceuticals
Phase 2 Terminated
NCT02644863 2016-05-24
Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer
Shenzhen Hornetcorn Bio-technology Company, LTD
Phase 2 Unknown
NCT00971841 2013-07-26
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00344552 2009-11-13
Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer
Bristol-Myers Squibb
Phase 2 Completed